Talaromyces marneffei

From WikiMD's WELLNESSPEDIA

Species of fungus


Talaromyces marneffei, formerly known as Penicillium marneffei, is a dimorphic fungus endemic to Southeast Asia. It is a significant opportunistic pathogen in immunocompromised individuals, particularly those with HIV/AIDS.

Morphology[edit]

Talaromyces marneffei exhibits dimorphism, meaning it can exist in two different forms depending on the temperature. At 25°C, it grows as a mold, producing characteristic greenish colonies with a red pigment that diffuses into the medium. At 37°C, it converts to a yeast-like form, which is the pathogenic form in humans.

Pathogenesis[edit]

Talaromyces marneffei infection, known as talaromycosis, occurs primarily in individuals with weakened immune systems. The fungus is inhaled as spores, which then convert to the yeast form in the body, leading to systemic infection. Symptoms include fever, weight loss, and respiratory issues, often resembling tuberculosis or histoplasmosis.

Diagnosis[edit]

Diagnosis of Talaromyces marneffei infection is typically made through culture of the organism from clinical specimens such as blood, bone marrow, or skin lesions. Microscopic examination can reveal the characteristic yeast cells with transverse septa.

Treatment[edit]

The treatment of choice for talaromycosis is amphotericin B, followed by itraconazole for maintenance therapy. Early diagnosis and treatment are crucial to prevent severe complications and mortality.

Epidemiology[edit]

Talaromyces marneffei is endemic to regions of Southeast Asia, including Thailand, Vietnam, and southern China. It is associated with bamboo rat habitats, although the exact ecological niche and mode of transmission to humans remain under investigation.

Prevention[edit]

Preventive measures for talaromycosis include avoiding exposure to environments where the fungus is endemic, particularly for individuals with compromised immune systems. Prophylactic antifungal therapy may be considered for high-risk patients.

Related pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.